Epiminder
Epiminder is an Australia-based medical technology company that developed the Minder System, the first FDA-authorized implantable continuous EEG monitoring device for adults with drug-resistant epilepsy. It serves neurologists and epilepsy centers via a four-component platform combining a sub-scalp implant, external wearable, smartphone app, and cloud portal enabling multi-year remote brain activity monitoring.
- Company typePublic
- Founded2018
- HeadquartersMelbourne, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Epiminder does
Epiminder is an Australian medical technology company that has developed and is commercializing the Minder System, the first and only FDA-authorized implantable continuous electroencephalogram (iCEM) monitoring device. Founded in 2018 as a research collaboration between the Bionics Institute, University of Melbourne, St Vincent's Hospital Melbourne, and Cochlear Limited, the company is headquartered in Melbourne and listed on the ASX under ticker EPI since December 2025. The company targets adults aged 18–75 with drug-resistant epilepsy — approximately 1.1 million US adults who have failed to achieve seizure freedom after two adequate anti-seizure medication trials.
The Minder System is a four-component integrated platform: a sub-scalp electrode implant placed behind the ear with multiple recording points enabling bilateral brain activity monitoring, an external Minder Wearable that receives wireless EEG transmissions via low-power Bluetooth, a Minder App for Android smartphones that uploads data to the cloud, and the Minder Cloud web portal where healthcare professionals can review and download patient EEG recordings. The architecture extends continuous monitoring from days (conventional scalp EEG) to multiple years — a UMPIRE study participant achieved a world-record five-year continuous EEG recording — and clinical data shows 88% of drug-resistant epilepsy patients received actionable clinical insights, including 23% with findings not possible with unilateral recording systems.
Epiminder's revenue model is anchored on one-time hardware sales of the Minder device at an assumed US$25,000 average selling price, supported by finalized Medicare reimbursement of US$27,700 per implant for 2026. New AMA Category III CPT codes effective January 2026 add a professional services revenue stream for implantation, interpretation, reporting, and remote monitoring, and a future subscription or SaaS model is planned for AI-enabled seizure forecasting software. Go-to-market is direct enterprise sales to leading US epilepsy centers and academic medical institutions, executed through a phased commercial rollout initiated in H2 2025 and supported by the DETECT clinical study generating real-world evidence across 19 participating sites including Mayo Clinic, University of Pennsylvania, Yale, Duke, Stanford, and Beth Israel Deaconess.
Epiminder firmographics
Firmographics- Name
- Epiminder
- Legal name
- Epi-Minder Pty Ltd
- Website
- https://epiminder.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Epiminder is an Australia-based medical technology company that developed the Minder System, the first FDA-authorized implantable continuous EEG monitoring device for adults with drug-resistant epilepsy. It serves neurologists and epilepsy centers via a four-component platform combining a sub-scalp implant, external wearable, smartphone app, and cloud portal enabling multi-year remote brain activity monitoring.
- Ownership category
- akta.pro rank
Epiminder industry classification
Industry- Product category
- Neurology Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industry
- Epilepsy & Seizure Disorders (HLAKAIAB)
Keywords
Where Epiminder is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
Epiminder business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Minder Device Sales: One-time hardware sales of the Minder implantable device system to hospitals and epilepsy treatment centers. Medicare reimbursement established at US$27,700 per device with assumed average selling price of US$25,000. Revenue recognition expected to begin following US commercial launch.
- Continuous EEG Monitoring Services: AMA Category III CPT codes established for implantation, interpretation, reporting, and remote monitoring services for continuous EEG data. New codes effective January 2026 enable healthcare providers to bill for services related to reviewing and interpreting Minder patient data and remote monitoring.
- Future Software Solutions: Planned integrated software solutions including AI-enabled seizure forecasting to extend clinical impact of the Minder device. Subscription or software-as-a-service model anticipated for future offerings.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Minder Device - Medicare Reimbursement |
| Other | Pay-as-you-go | CPT Codes for Implantation and Monitoring Services |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Epiminder product offering
Product offeringCore offering
Epiminder develops, manufactures, and commercializes the Minder System, a first-of-its-kind FDA-authorized implantable continuous EEG monitoring (iCEM) device for patients with drug-resistant epilepsy. The integrated system comprises a sub-scalp electrode implant, an external wearable receiver, a smartphone app, and a secure cloud platform enabling healthcare professionals to remotely monitor years of continuous brain activity data for clinical assessment and surgical planning.
Product overview
Epiminder offers the Minder® System, a comprehensive implantable continuous EEG monitoring (iCEM) solution. The system comprises four integrated components: the Minder Implant (sub-scalp electrode placed behind the ear for bilateral brain activity monitoring), Minder Wearable (external receiver worn by patient), Minder App (Android smartphone application for data transmission), and Minder Cloud (secure web portal for healthcare professionals). The company is also conducting the DETECT clinical study program, a prospective randomized controlled trial evaluating the system in US patients with drug-resistant epilepsy.
Differentiator
Problem solved
Functional benefit
Brands
- Minder System: Implantable continuous EEG monitoring (iCEM) system for epilepsy patients
- Minder Cloud
- Minder App
- DETECT Study
- UMPIRE Study
Products and services
- Minder System The Minder System is an implantable continuous EEG monitoring (iCEM) system providing years-long continuous brain activity monitoring for patients aged 18-75 with drug-resistant epilepsy. The integrated system comprises the Minder Implant (sub-scalp electrode placed behind the ear with bilateral recording capability), Minder Wearable (external wireless receiver), Minder App (Android smartphone application for data transmission and seizure diary), and Minder Cloud (secure web portal for healthcare professional access). It is sold to hospitals and epilepsy treatment centers for use by neurologists and epileptologists managing patients with drug-resistant epilepsy.
Quantifiable outcome
- 88% of patients in UMPIRE study received actionable clinical insights
- +6 more outcomes
Companies that use Epiminder
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
Epiminder technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Epiminder partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered strategic and core.
- American Clinical Neurophysiology Society (ACNS)strategicPartnership with ACNS to help establish new Category III CPT codes for interpretation and reporting of continuous EEG data from sub-scalp implantable monitoring systems. ACNS worked with AMA to create codes enabling neurologists to bill for reviewing and interpreting Minder patient data.
- Seer MedicalstrategicStrategic collaboration to accelerate ultra-long term EEG monitoring through combined Minder implant and Seer Cloud technology. Seer provides advanced algorithms and data curation for seizure detection and forecasting. Seer has monitored nearly 6,000 Australians with at-home video-EEG-ECG equipment. Participated in $16m bridge financing round.
- Bionics InstitutecoreInternationally recognized independent medical research institute and co-founder of Epiminder. Led research on devices to alleviate symptoms of neurological disorders. Provided technological expertise in epilepsy seizure monitoring and bionic device development through research collaboration.
- St Vincent's Hospital MelbournecoreWorld-leading research hospital and co-founder of Epiminder. Professor Mark Cook serves as neurologist and chair of medicine. Provided clinical research expertise and was site of initial Minder trials. Part of ACMD biomedical engineering research centre.
- University of MelbournecoreGlobal leader in higher education and co-founder of Epiminder. Professor Mark Cook serves as Chair of Medicine. Contributed research leadership and academic expertise to epilepsy monitoring technology development.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Epiminder competitors and assessment
Company assessmentEmerging players
- Ceribell: Ceribell provides rapid-response EEG headbands and cloud-based seizure detection for hospitalized patients. While non-implantable, Ceribell competes in the EEG monitoring category and overlaps in epileptologist and neurology customer relationships.
- iRhythm Technologies: iRhythm's Zio long-term continuous cardiac monitor is a useful analog: a wearable + AI cloud platform enabling multi-day remote monitoring with reimbursement established and epileptologist/cardiology customer workflow parallels. Strong business-model comparison for the recurring-monitoring thesis.
Broad incumbents
- Boston Scientific: Boston Scientific acquired the VNS franchise for epilepsy and has broad neuromodulation portfolio across multiple indications. The company is a broad incumbent in the device-based epilepsy treatment space that epileptologists already work with.
- Preventice Solutions (Boston Scientific): Boston Scientific's insertable cardiac monitor business (formerly Preventice BodyGuardian) offers implantable continuous monitoring with cloud analytics in cardiology. The technology and business model closely parallel Epiminder's Minder system applied to neurology.
- Natus Medical: Natus (now part of Natus Neuro) manufactures conventional scalp EEG systems, EMG, and intraoperative monitoring equipment used in epilepsy monitoring units. They are the incumbent EEG equipment supplier at many of the same centers Epiminder is targeting.
- Medtronic: Medtronic offers Deep Brain Stimulation (DBS) systems, including the Percept PC with BrainSense EEG capability, approved for epilepsy among other indications. As a global medtech incumbent, Medtronic has the resources to develop competitive continuous EEG neuro-monitoring offerings for the same epileptologist channel.
Direct peers
- NeuroPace: NeuroPace makes the RNS System, the only other FDA-approved implantable brain stimulation device for drug-resistant epilepsy. While RNS provides responsive neurostimulation rather than continuous EEG recording, both companies target the same patient population with implantable cranial devices and compete for the same epileptologist customers.
- LivaNova: LivaNova markets Vagus Nerve Stimulation (VNS) Therapy for drug-resistant epilepsy. Epiminder's CEO previously ran LivaNova's neuromodulation division. Both compete for refractory epilepsy patients and epileptologist prescribing decisions.
- Seer Medical: Seer Medical provides at-home video-EEG-ECG monitoring and cloud-based seizure analytics, and is both a strategic collaborator and bridge-round investor in Epiminder. Seer's non-invasive at-home offering addresses the same patient population with overlapping AI/seizure-detection technology.
Regional players
- Compumedics: Compumedics is an Australia-based peer (like Epiminder) that manufactures EEG, sleep, and neurological monitoring equipment sold globally. It addresses the same customer base (epilepsy monitoring units, neurologists) with conventional scalp EEG rather than implantable solutions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Epiminder social profiles
Digital presenceEpiminder compliance and trust
Trust signalCompliance4 records
Epiminder financial estimates
Financial estimateRevenue estimate
Valuation estimate
Epiminder leadership team
Management profileNumber of profiles
Profiles14 records
Epiminder subsidiaries and ownership
Company hierarchySubsidiaries1 record
Epiminder funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Epiminder M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Epiminder
What does Epiminder do?
Epiminder develops, manufactures, and commercializes the Minder System, a first-of-its-kind FDA-authorized implantable continuous EEG monitoring (iCEM) device for patients with drug-resistant epilepsy. The integrated system comprises a sub-scalp electrode implant, an external wearable receiver, a smartphone app, and a secure cloud platform enabling healthcare professionals to remotely monitor years of continuous brain activity data for clinical assessment and surgical planning.
Is Epiminder a public or private company?
Epiminder is a public company. It is classified as public and is currently operating.
When was Epiminder founded?
Epiminder was founded in 2018. It employs 11 to 50 people.
Where is Epiminder based?
Epiminder is headquartered in Melbourne, Australia, in the Oceania region.
How does Epiminder make money?
Three revenue lines are on record. Minder Device Sales are the primary driver. The others are continuous EEG Monitoring Services and future Software Solutions.
Who are Epiminder's main competitors?
Emerging players on record are Ceribell and iRhythm Technologies. Broad incumbents are Boston Scientific, Preventice Solutions (Boston Scientific), Natus Medical and Medtronic. Direct peers are NeuroPace, LivaNova and Seer Medical. Compumedics is listed as a regional player.
Does Epiminder have an API?
No public API is recorded for Epiminder.
What industry is Epiminder in?
Epiminder's product category is Neurology Medical Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLAKAIAB, Epilepsy & Seizure Disorders. Its NAICS code is 334510 and its SIC code is 3845.